The University of Chicago Header Logo

Connection

Tao Xie to Male

Back to Details
This is a "connection" page, showing publications Tao Xie has written about Male.
Tao Xie
Connection Strength
0.494
Male
  1. Disparities in diagnosis, treatment and survival between Black and White Parkinson patients. Parkinsonism Relat Disord. 2021 06; 87:7-12.
    View in: PubMed
    Score: 0.039
  2. Interference of subcutaneous implantable cardioverter defibrillator by deep brain stimulation. Parkinsonism Relat Disord. 2020 12; 81:75-77.
    View in: PubMed
    Score: 0.037
  3. Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. J Neurol Neurosurg Psychiatry. 2018 09; 89(9):989-994.
    View in: PubMed
    Score: 0.031
  4. Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. J Neurol. 2016 Nov; 263(11):2302-2307.
    View in: PubMed
    Score: 0.028
  5. Author Response. Neurology. 2015 Aug 11; 85(6):557.
    View in: PubMed
    Score: 0.026
  6. Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS. Neurology. 2015 Aug 04; 85(5):479-80.
    View in: PubMed
    Score: 0.026
  7. Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology. 2015 Jan 27; 84(4):415-20.
    View in: PubMed
    Score: 0.025
  8. DBS reduced hemichorea associated with a developmental venous anomaly and microbleeding in STN. Neurology. 2014 Feb 18; 82(7):636-7.
    View in: PubMed
    Score: 0.023
  9. Diagnostic biomarkers of Parkinson's disease: what gain at what cost? J Neurol Neurosurg Psychiatry. 2012 Aug; 83(8):769.
    View in: PubMed
    Score: 0.021
  10. Effect of stimulation frequency on immediate freezing of gait in newly activated STN DBS in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2012 Oct; 83(10):1015-7.
    View in: PubMed
    Score: 0.021
  11. Treatment of fragile X-associated tremor/ataxia syndrome with unilateral deep brain stimulation. Mov Disord. 2012 May; 27(6):799-800.
    View in: PubMed
    Score: 0.021
  12. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism Relat Disord. 2019 03; 60:138-145.
    View in: PubMed
    Score: 0.016
  13. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 01 23; 90(4):e273-e281.
    View in: PubMed
    Score: 0.015
  14. Dystonia treatment: Patterns of medication use in an international cohort. Neurology. 2017 Feb 07; 88(6):543-550.
    View in: PubMed
    Score: 0.014
  15. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology. 2016 Nov 08; 87(19):2016-2025.
    View in: PubMed
    Score: 0.014
  16. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology. 2006 Dec; 31(12):2639-51.
    View in: PubMed
    Score: 0.013
  17. Clinical, Radiological and Pathological Features of a Large American Cohort of Spinocerebellar Ataxia (SCA27B). Ann Neurol. 2024 Dec; 96(6):1092-1103.
    View in: PubMed
    Score: 0.012
  18. Identification and characterization of metallothionein-1 and -2 gene expression in the context of (+/-)3,4-methylenedioxymethamphetamine-induced toxicity to brain dopaminergic neurons. J Neurosci. 2004 Aug 11; 24(32):7043-50.
    View in: PubMed
    Score: 0.012
  19. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.
    View in: PubMed
    Score: 0.012
  20. Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity. J Neurosci. 2002 Jan 01; 22(1):274-83.
    View in: PubMed
    Score: 0.010
  21. Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J Neurosci. 2000 Oct 15; 20(20):7838-45.
    View in: PubMed
    Score: 0.009
  22. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
    View in: PubMed
    Score: 0.009
  23. Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. Hum Brain Mapp. 2019 12 01; 40(17):5094-5107.
    View in: PubMed
    Score: 0.009
  24. Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism Relat Disord. 2019 08; 65:178-183.
    View in: PubMed
    Score: 0.009
  25. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019 06; 18(6):549-558.
    View in: PubMed
    Score: 0.009
  26. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Mov Disord. 2018 02; 33(2):282-288.
    View in: PubMed
    Score: 0.008
  27. G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov Disord. 1997 May; 12(3):426-7.
    View in: PubMed
    Score: 0.007
  28. Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord. 2016 12; 31(12):1874-1882.
    View in: PubMed
    Score: 0.007
  29. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Mov Disord. 2016 06; 31(6):924-32.
    View in: PubMed
    Score: 0.007
  30. A murine dopamine neuron-specific cDNA library and microarray: increased COX1 expression during methamphetamine neurotoxicity. Neurobiol Dis. 2001 Oct; 8(5):822-33.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.